The role of histone acetyltransferases in normal and malignant hematopoiesis

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Sun, Xiao Jian ^a,b   Man, Na ^a,b   Tan, Yurong ^a,b   Nimer, Stephen D ^a,b   Wang, Lan ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Hematological malignancies; Hematopoiesis; Hematopoietic stem cells; Histone acetyltransferases; Transcriptional regulation

Indexed keywords

BROMODOMAIN INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE PCAF; MIXED LINEAGE LEUKEMIA PROTEIN; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; NOTCH3 RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; DNA DAMAGE; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; LEUKEMOGENESIS; MALIGNANT HEMATOPOIESIS; MYELOID PROGENITOR CELL; NONHUMAN; ONCOGENE C MYB; PROTEIN ACETYLATION; PROTEIN ASSEMBLY; PROTEIN HOMEOSTASIS; REVIEW; T CELL LEUKEMIA; TUMOR IMMUNITY;

EID: 84934282991     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00108     Document Type: Review

References (111)

1. Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (2012) 345(1):7-21. doi: 10.1002/ardp.201100209.
2. Friedmann DR, Marmorstein R. Structure and mechanism of non-histone protein acetyltransferase enzymes. FEBS J (2013) 280(22):5570-81. doi:10.1111/febs.12373.
3. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, et al. New nomenclature for chromatin-modifying enzymes. Cell (2007) 131(4):633-6. doi:10.1016/j.cell.2007.10.039.
4. Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M, et al. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem (2004) 279(15):15630-8. doi:10.1074/jbc.M400355200.
5. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (2011) 333(6043):765-9. doi:10.1126/science.1201662.
6. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell (1997) 90(4):595-606. doi:10.1016/S0092-8674(00)80521-8.
7. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep (2003) 4(5):484-90. doi:10.1038/sj.embor.embor821.
8. Santander VS, Bisig CG, Purro SA, Casale CH, Arce CA, Barra HS. Tubulin must be acetylated in order to form a complex with membrane Na(+), K(+)-ATPase and to inhibit its enzyme activity. Mol Cell Biochem (2006) 291(1-2):167-74. doi:10.1007/s11010-006-9212-9.
9. Ivanov D, Schleiffer A, Eisenhaber F, Mechtler K, Haering CH, Nasmyth K. Eco1 is a novel acetyltransferase that can acetylate proteins involved in cohesion. Curr Biol (2002) 12(4):323-8. doi:10.1016/S0960-9822(02)00681-4.
10. Buerki C, Rothgiesser KM, Valovka T, Owen HR, Rehrauer H, Fey M, et al. Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65. Nucleic Acids Res (2008) 36(5):1665-80. doi:10.1093/nar/gkn003.
11. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem (2001) 70:81-120. doi:10.1146/annurev.biochem.70.1.81.
12. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 17(5):471-82. doi:10.1016/j.chembiol.2010.03.006.
13. Voss AK, Thomas T. MYST family histone acetyltransferases take center stage in stem cells and development. Bioessays (2009) 31(10):1050-61. doi:10.1002/bies.200900051.
14. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 90(3):569-80. doi:10.1016/S0092-8674(00)80516-4.
15. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 389(6647):194-8. doi:10.1038/38304.
16. Blanco-Garcia N, Asensio-Juan E, de la Cruz X, Martinez-Balbas MA. Autoacetylation regulates P/CAF nuclear localization. J Biol Chem (2009) 284(3):1343-52. doi:10.1074/jbc.M806075200.
17. Mishima Y, Miyagi S, Saraya A, Negishi M, Endoh M, Endo TA, et al. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. Blood (2011) 118(9):2443-53. doi:10.1182/blood-2011-01-331892.
18. Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers GP. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood (2007) 110(8):2864-71. doi:10.1182/blood-2007-01-065201.
19. Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets (2006) 10(1):51-68. doi:10.1517/14728222.10.1.51.
20. Huang HT, Kathrein KL, Barton A, Gitlin Z, Huang YH, Ward TP, et al. A network of epigenetic regulators guides developmental haematopoiesis in vivo. Nat Cell Biol (2013) 15(12):1516-25. doi:10.1038/ncb2870.
21. Shen H, Chen Z, Ding X, Qi X, Cen J, Wang Y, et al. BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression. J Cell Mol Med (2014) 18(6):1004-17. doi:10.1111/jcmm.12246.
22. Kosan C, Ginter T, Heinzel T, Kramer OH. STAT5 acetylation: mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 2(4):e26102. doi:10.4161/jkst.26102.
23. Holmlund T, Lindberg MJ, Grander D, Wallberg AE. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia (2013) 27(3):578-85. doi:10.1038/leu.2012.265.
24. Joosten M, Seitz V, Zimmermann K, Sommerfeld A, Berg E, Lenze D, et al. Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype. Haematologica (2013) 98(2):247-54. doi:10.3324/haematol.2011.054619.
25. Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, et al. Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene (2012) 31(33):3807-17. doi:10.1038/onc.2011.533.
26. Perez-Campo FM, Costa G, Lie-a-Ling M, Kouskoff V, Lacaud G. The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis. Immunology (2013) 139(2):161-5. doi:10.1111/imm.12072.
27. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 13(5):337-56. doi:10.1038/nrd4286.
28. Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem (2012) 287(51):43137-55. doi:10.1074/jbc.M112.413047.
29. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 24(6):777-90. doi:10.1016/j.ccr.2013.11.003.
30. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene (2014) 33(22):2928-37. doi:10.1038/onc.2013.242.
31. Mottok A, Gascoyne RD. Bromodomain inhibition in diffuse large B-cell lymphoma - giving MYC a brake. Clin Cancer Res (2015) 21(1):4-6. doi:10.1158/1078-0432.CCR-14-1651.
32. Hnisz D, Abraham BJ, Lau A, Saint-André V, Sigova AA, Hoke HA, et al. Super-enhancers in the control of cell identity and disease. Cell (2013) 155:934-47. doi:10.1016/j.cell.2013.09.053.
33. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 153:320-34. doi:10.1016/j.cell.2013.03.036.
34. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 346(6215):1373-7. doi:10.1126/science.1259037.
35. Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia (2014) 28(8):1725-35. doi:10.1038/leu.2014.70.
36. Qian J, Wang Q, Dose M, Pruett N, Kieffer-Kwon KR, Resch W, et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell (2014) 159(7):1524-37. doi:10.1016/j.cell.2014.11.013.
37. Marushige K. Activation of chromatin by acetylation of histone side chains. Proc Natl Acad Sci U S A (1976) 73(11):3937-41. doi:10.1073/pnas.73.11.3937.
38. Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res (2010) 38(15):4958-69. doi:10.1093/nar/gkq244.
39. Oike Y, Takakura N, Hata A, Kaname T, Akizuki M, Yamaguchi Y, et al. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood (1999) 93(9):2771-9.
40. Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A, et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol Cell Biol (2011) 31(24):5046-60. doi:10.1128/MCB. 05830-11.
41. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev (2000) 14(3):272-7. doi:10.1101/gad.14.3.272.
42. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A (2002) 99(23):14789-94. doi:10.1073/pnas.232568499.
43. Thomas T, Corcoran LM, Gugasyan R, Dixon MP, Brodnicki T, Nutt SL, et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev (2006) 20(9):1175-86. doi:10.1101/gad.1382606.
44. Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood (2009) 113(20):4866-74. doi:10.1182/blood-2008-04-152017.
45. Perez-Campo FM, Costa G, Lie ALM, Stifani S, Kouskoff V, Lacaud G. MOZ-mediated repression of p16 is critical for the self-renewal of neural and hematopoietic stem cells. Stem Cells (2014) 32(6):1591-601. doi:10.1002/stem.1606.
46. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL. Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood (2009) 114(23):4804-12. doi:10.1182/blood-2009-04-217794.
47. Kasper LH, Boussouar F, Ney PA, Jackson CW, Rehg J, van Deursen JM, et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature (2002) 419(6908):738-43. doi:10.1038/nature01062.
48. Kasper LH, Fukuyama T, Lerach S, Chang Y, Xu W, Wu S, et al. Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression. PLoS One (2013) 8(12):e82684. doi:10.1371/journal.pone.0082684.
49. Hung T, Binda O, Champagne KS, Kuo AJ, Johnson K, Chang HY, et al. ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Mol Cell (2009) 33(2):248-56. doi:10.1016/j.molcel.2008.12.016.
50. Saksouk N, Avvakumov N, Champagne KS, Hung T, Doyon Y, Cayrou C, et al. HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol Cell (2009) 33(2):257-65. doi:10.1016/j.molcel.2009.01.007.
51. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood (2010) 115(5):965-74. doi:10.1182/blood-2009-02-207118.
52. Du T, Nagai Y, Xiao Y, Greene MI, Zhang H. Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp Mol Pathol (2013) 95(1):38-45. doi:10.1016/j.yexmp.2013.04.003.
53. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146(5):772-84. doi:10.1016/j.cell.2011.07.033.
54. Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, et al. Inhibition of p300 impairs Foxp3(+) T regulatory cell function and promotes antitumor immunity. Nat Med (2013) 19(9):1173-7. doi:10.1038/nm.3286.
55. Kikuchi H, Kuribayashi F, Takami Y, Imajoh-Ohmi S, Nakayama T. GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk. Biochem Biophys Res Commun (2011) 405(4):657-61. doi:10.1016/j.bbrc.2011.01.088.
56. Pattabiraman DR, Sun J, Dowhan DH, Ishii S, Gonda TJ. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability. Mol Cancer Res (2009) 7(9):1477-86. doi:10.1158/1541-7786.MCR-09-0070.
57. Zhao L, Glazov EA, Pattabiraman DR, Al-Owaidi F, Zhang P, Brown MA, et al. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. Nucleic Acids Res (2011) 39(11):4664-79. doi:10.1093/nar/gkr024.
58. Pattabiraman DR, McGirr C, Shakhbazov K, Barbier V, Krishnan K, Mukhopadhyay P, et al. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood (2014) 123(17):2682-90. doi:10.1182/blood-2012-02-413187.
59. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood (1997) 89(11):3945-50.
60. Santillan DA, Theisler CM, Ryan AS, Popovic R, Stuart T, Zhou MM, et al. Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype. Cancer Res (2006) 66(20):10032-9. doi:10.1158/0008-5472.CAN-06-2597.
61. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature (2013) 500(7460):93-7. doi:10.1038/nature12287.
62. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 448(7157):1063-7. doi:10.1038/nature06055.
63. Zhao H, Jin S, Gewirtz AM. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia. J Biol Chem (2012) 287(2):925-34. doi:10.1074/jbc.M111.279950.
64. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood (1998) 91(9):3127-33.
65. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood (1998) 92(6):2118-22.
66. Carapeti M, Aguiar RC, Watmore AE, Goldman JM, Cross NC. Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Cancer Genet Cytogenet (1999) 113(1):70-2. doi:10.1016/S0165-4608(99)00007-2.
67. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 6(6):587-96. doi:10.1016/j.ccr.2004.10.015.
68. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR, et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell (2003) 3(3):259-71. doi:10.1016/S1535-6108(03)00051-5.
69. Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, et al. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol (2005) 25(3):988-1002. doi:10.1128/MCB.25.3.988-1002.2005.
70. Collins HM, Kindle KB, Matsuda S, Ryan C, Troke PJ, Kalkhoven E, et al. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators. J Biol Chem (2006) 281(25):17124-33. doi:10.1074/jbc.M602633200.
71. Yin H, Glass J, Blanchard KL. MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2. Mol Cancer (2007) 6:51. doi:10.1186/1476-4598-6-51.
72. Zhuravleva J, Paggetti J, Martin L, Hammann A, Solary E, Bastie JN, et al. MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol (2008) 143(3):378-82. doi:10.1111/j.1365-2141.2008.07362.x.
73. Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K, et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med (2010) 16(5):580-5. doi:10.1038/nm.2122.
74. Tam WF, Hahnel PS, Schuler A, Lee BH, Okabe R, Zhu N, et al. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res (2013) 73(1):373-84. doi:10.1158/0008-5472.CAN-12-0255.
75. Shima H, Yamagata K, Aikawa Y, Shino M, Koseki H, Shimada H, et al. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion. Int J Hematol (2014) 99(1):21-31. doi:10.1007/s12185-013-1466-x.
76. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 14(1):33-41. doi:10.1038/ng0996-33.
77. Panagopoulos I, Isaksson M, Lindvall C, Bjorkholm M, Ahlgren T, Fioretos T, et al. RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer (2000) 28(4):415-24. doi:10.1002/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I.
78. Rozman M, Camos M, Colomer D, Villamor N, Esteve J, Costa D, et al. Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer (2004) 40(2):140-5. doi:10.1002/gcc.20022.
79. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J (2001) 20(24):7184-96. doi:10.1093/emboj/20.24.7184.
80. Chan EM, Chan RJ, Comer EM, Goulet RJ III, Crean CD, Brown ZD, et al. MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol (2007) 35(12):1782-92. doi:10.1016/j.exphem.2007.07.015.
81. Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I. Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J Biol Chem (2009) 284(1):237-44. doi:10.1074/jbc.M805101200.
82. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia (2001) 15(1):89-94. doi:10.1038/sj.leu.2401983.
83. Imamura T, Kakazu N, Hibi S, Morimoto A, Fukushima Y, Ijuin I, et al. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11). Genes Chromosomes Cancer (2003) 36(4):413-9. doi:10.1002/gcc.10172.
84. Senyuk V, Sinha KK, Chakraborty S, Buonamici S, Nucifora G. P/CAF and GCN5 acetylate the AML1/MDS1/EVI1 fusion oncoprotein. Biochem Biophys Res Commun (2003) 307(4):980-6. doi:10.1016/S0006-291X(03)01288-9.
85. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res (2004) 32(3):959-76. doi:10.1093/nar/gkh252.
86. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature (2000) 408(6810):377-81. doi:10.1038/35042612.
87. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 20(22):8458-67. doi:10.1128/MCB.20.22.8458-8467.2000.
88. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell (2001) 8(6):1243-54. doi:10.1016/S1097-2765(01)00414-2.
89. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J (2001) 20(6):1331-40. doi:10.1093/emboj/20.6.1331.
90. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol (2006) 173(4):533-44. doi:10.1083/jcb.200512059.
91. Li AG, Piluso LG, Cai X, Gadd BJ, Ladurner AG, Liu X. An acetylation switch in p53 mediates holo-TFIID recruitment. Mol Cell (2007) 28(3):408-21. doi:10.1016/j.molcel.2007.09.006.
92. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature (2008) 451(7178):583-6. doi:10.1038/nature06500.
93. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 451(7178):587-90. doi:10.1038/nature06515.
94. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol (1999) 19(2):1202-9.
95. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 12(18):2831-41. doi:10.1101/gad.12.18.2831.
96. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 101(8):2259-64. doi:10.1073/pnas.0308762101.
97. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 26(7):2782-90. doi:10.1128/MCB.26.7.2782-2790.2006.
98. Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem (2003) 278(28):25568-76. doi:10.1074/jbc.M212574200.
99. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev (2000) 14(13):1553-77. doi:10.1101/gad.14.13.1553.
100. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell (2006) 24(6):841-51. doi:10.1016/j.molcel.2006.11.026.
101. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell (2006) 24(6):827-39. doi:10.1016/j.molcel.2006.11.021.
102. Mellert H, Sykes SM, Murphy ME, McMahon SB. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle (2007) 6(11):1304-6. doi:10.4161/cc.6.11.4343.
103. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 25(13):5389-95. doi:10.1128/MCB.25.13.5389-5395.2005.
104. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell (2008) 133(4):612-26. doi:10.1016/j.cell.2008.06.005.
105. Nishino T, Wang C, Mochizuki-Kashio M, Osawa M, Nakauchi H, Iwama A. Ex vivo expansion of human hematopoietic stem cells by garcinol, a potent inhibitor of histone acetyltransferase. PLoS One (2011) 6(9):e24298. doi:10.1371/journal.pone.0024298.
106. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One (2013) 8(2):e55481. doi:10.1371/journal.pone.0055481.
107. Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH, Kang HB, et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res (2009) 69(2):583-92. doi:10.1158/0008-5472.CAN-08-2442.
108. Yang H, Pinello CE, Luo J, Li D, Wang Y, Zhao LY, et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther (2013) 12(5):610-20. doi:10.1158/1535-7163.MCT-12-0930.
109. Kusio-Kobialka M, Dudka-Ruszkowska W, Ghizzoni M, Dekker FJ, Piwocka K. Inhibition of PCAF by anacardic acid derivative leads to apoptosis and breaks resistance to DNA damage in BCR-ABL-expressing cells. Anticancer Agents Med Chem (2013) 13(5):762-7. doi:10.2174/1871520611313050010.
110. Secci D, Carradori S, Bizzarri B, Bolasco A, Ballario P, Patramani Z, et al. Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors. Bioorg Med Chem (2014) 22(5):1680-9. doi:10.1016/j.bmc.2014.01.022.
111. Chimenti F, Bizzarri B, Maccioni E, Secci D, Bolasco A, Chimenti P, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone. J Med Chem (2009) 52(2):530-6. doi:10.1021/jm800885d.